Adimab Announces New Partnerships with Acceleron, Oncothyreon, Surface Oncology and Potenza

January 09, 2015 Lebanon, NH PDF

Adimab, LLC, the technology leader in the discovery of monoclonal and bispecific antibodies, today announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc., Surface Oncology, Inc. and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner.

“These new partnerships epitomize the growing trend of highly innovative discovery programs originating in smaller and mid-sized biotech companies,” said Tillman Gerngross, Chief Executive Officer and co-founder of Adimab. “The Adimab platform is the optimal tool to probe and elucidate complex biology, and we look forward to deploying our capabilities towards the unique problems our partners are working on.”

Adimab’s New Partners Share Their Enthusiasm

“Acceleron has designed, manufactured, and developed several receptor fusion proteins and as we continue to expand our pipeline, we believe having access to a world-class platform to rapidly generate antibodies will be a valuable addition to our discovery efforts,” said John Knopf, Chief Executive Officer at Acceleron. “After surveying the antibody technology landscape, we concluded that Adimab is the best option for us and we look forward to a successful partnership.”

“Our partnership with Adimab is enabling Surface Oncology to meet its strategic goals,” stated Scott Chappel, Chief Technology Officer at Surface Oncology. “Adimab’s technology is rapidly delivering an impressive breadth and quality of antibodies.”

“We are focused on rapidly advancing therapeutic antibodies toward the clinic, and the Adimab technology is key to helping us achieve this goal,” said Dan Hicklin, Ph.D., President and Chief Executive Officer at Potenza. “Adimab delivered antibodies to us within two months of starting the first project.”

Under the terms of each of these four agreements, Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies or bispecifics for its partners. These agreements generally grant Adimab’s partners the right to develop and commercialize antibodies and, in some instances, bispecifics generated during the collaboration for potential use as therapeutic products. Adimab’s partners will typically fund research at Adimab and have the option to exclusively license antibodies and bispecifics generated during the collaboration. While the terms of individual agreements may vary, if a partner exercises its option for a particular target, Adimab will usually receive license fees, clinical milestones and royalties on therapeutic product sales.

New Milestones Achieved by Current Partners

Genentech has exercised a commercial license to antibodies identified by Adimab to an undisclosed target. Genentech has exclusive development and commercialization rights to such antibodies.

In addition, Adimab announced the achievement of technical milestones from its ongoing collaborations with Merck & Co., Innovent, Acceleron, Surface Oncology and Potenza.

Over the past five years, Adimab has established funded discovery collaborations with over 25 companies. These funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin and Celgene. Adimab has strategically partnered with many other companies as well, including Merrimack, Five Prime, Jounce, Innovent, Alector and Arsanis. In addition, Adimab has transferred its platform for broad use to GSK, Biogen Idec and Novo Nordisk.

About Adimab

Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human lgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies and bispecifics that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad array of technology access arrangements.


Guy Van Meter
VP of Business Development, Adimab LLC
(603) 653-5775